Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.10 USD

119.10
722,614

+0.60 (0.51%)

Updated Sep 4, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group

by Zacks Equity Research

Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

by Zacks Equity Research

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.

Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.

    Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises

    by Zacks Equity Research

    Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.

    Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates

    by Zacks Equity Research

    Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

    Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View

    by Zacks Equity Research

    Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.

    Kinjel Shah headshot

    Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

    by Kinjel Shah

    Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

    Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN

    by Zacks Equity Research

    Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.

    Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.

    Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth

    by Zacks Equity Research

    Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

    Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug

    by Zacks Equity Research

    The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.

    KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study

    by Zacks Equity Research

    KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

    BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

    by Zacks Equity Research

    BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

      BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study

      by Zacks Equity Research

      BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.

      Kinjel Shah headshot

      Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY

      by Kinjel Shah

      Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.

      Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

      by Zacks Equity Research

      Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

      Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer

      by Zacks Equity Research

      Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.

      Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder

      by Zacks Equity Research

      The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.

      Accenture (ACN) Joins Health Data Collaborative, AI4BetterHearts

      by Zacks Equity Research

      Accenture's (ACN) goal behind joining the collaborative is to support and advance cardiovascular disease prevention through integrating innovation and emerging technologies.

      Kinjel Shah headshot

      Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS

      by Kinjel Shah

      FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.

      Novartis (NVS) Beovu Gets Label Expansion for DME in EU

      by Zacks Equity Research

      Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

      The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences

      by Zacks Equity Research

      Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.